Development of a molecular profiling assay for circulating tumor cells (CTCs) utilizing automated multiplexed in situ hybridization for metastatic castrate-resistant prostate cancer (mCRPC).

@article{Nagy2012DevelopmentOA,
  title={Development of a molecular profiling assay for circulating tumor cells (CTCs) utilizing automated multiplexed in situ hybridization for metastatic castrate-resistant prostate cancer (mCRPC).},
  author={Dea Nagy and Mateus Crespo and Gerhardt Attard and Susana Miranda and Karl E Garsha and Ubaradka G Sathyanarayana and Steve Yun and Michael Otter and Phillip Miller and Gary A. Pestano and Johann S de Bono and Ryan Dittamore},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 5_suppl},
  pages={39}
}
39 Background: ERG gene rearrangements lead to overexpression of the ERG oncogene in 50% of localized and metastatic prostate cancers. Recent studies have indicated that this gene fusion correlates with androgen sensitivity in prostate cancer patients and an association with increased DNA Repair activity (PARP1). The PTEN tumor suppressor has also been shown to regulate the AKT pathway, and related to increased PARP1 activity. We hypothesized that future PARP1 inhibitors and other targeted… CONTINUE READING
0 Extracted Citations
0 Extracted References
Similar Papers

Similar Papers

Loading similar papers…